SUPPLEMENT

Q3 2025 — Earnings infographic

Q3 2025PDF · 1 pages374 KB
Johnson & Johnson
delivered another strong
performance in the third
quarter fueled by the depth
and strength of our portfolio
and significant progress across
our pipeline. With a sharpened
focus on the six priority areas
of Oncology, Immunology,
Neuroscience, Cardiovascular,
Surgery and Vision, Johnson &
Johnson is in a new era of
accelerated growth and
innovation, with pioneering
treatments that will continue
to transform lives.
3rd Quarter 2025 Results
3rd 	Quarter 2025 Sales
$24.0B 	6.8%
Worldwide increased 	Worldwide increased	Excluding the impact of
translational currency
For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson’s earnings release issued on October 14, 2025 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx
1 	Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
2 	Non-GAAP measure; excludes the impact of translational currency.
Note: Values may be rounded
Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on
current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements”
included in the Johnson & Johnson earnings release issued on October 14, 2025 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
$15.6
billion
Worldwide Innovative Medicine sales
Innovative Medicine worldwide reported sales increased
6.8% or 5.3% operationally2. Stelara impacted results2
by ~(1,070) basis points. Primary operational drivers:
$8.4
billion
Worldwide MedTech sales
MedTech worldwide reported sales
increased 6.8% or 5.6% operationally2
Primary operational drivers:
Shockwave 	Surgical Vision
Joaquin Duato
Chairman & Chief
Executive Officer
Johnson & Johnson Wound Closure
5.4%1
Electrophysiology
Contact Lenses
Adjusted diluted earnings per share1
15.7%	$2.80 Worldwide increased
Stelara impacted results by ~(640) basis points
Diluted earnings per share (EPS)
91.0%	$2.12 Worldwide increased
Biosurgery
Abiomed

-- 1 of 1 --